MK-8777

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Attention Deficit Hyperactivity DisorderDepression

Phase 2

Dose Finding Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)(174007/P05805/MK-8777-003)

CompletedNCT00610441

Merck Sharp & Dohme LLCAttention Deficit Hyperactivity Disorder

Start: 2008-04-01End: 2009-03-09Updated: 2018-10-24

Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)

CompletedNCT00610649

Merck Sharp & Dohme LLCDepression

Start: 2007-09-20End: 2008-12-10Updated: 2018-11-06